Characterization of brain‐derived extracellular vesicle lipids in Alzheimer's disease

Abstract

Lipid dyshomeostasis is associated with the most common form of dementia, Alzheimer's disease (AD). Substantial progress has been made in identifying positron emission tomography and cerebrospinal fluid biomarkers for AD, but they have limited use as front‐line diagnostic tools. Extracellular vesicles (EVs) are released by all cells and contain a subset of their parental cell composition, including lipids. EVs are released from the brain into the periphery, providing a potential source of tissue and disease specific lipid biomarkers. However, the EV lipidome of the central nervous system is currently unknown and the potential of brain‐derived EVs (BDEVs) to inform on lipid dyshomeostasis in AD remains unclear. The aim of this study was to reveal the lipid composition of BDEVs in human frontal cortex, and to determine whether BDEVs have an altered lipid profile in AD. Using semi‐quantitative mass spectrometry, we describe the BDEV lipidome, covering four lipid categories, 17 lipid classes and 692 lipid molecules. BDEVs were enriched in glycerophosphoserine (PS) lipids, a characteristic of small EVs. Here we further report that BDEVs are enriched in ether‐containing PS lipids, a finding that further establishes ether lipids as a feature of EVs. BDEVs in the AD frontal cortex offered improved detection of dysregulated lipids in AD over global lipid profiling of this brain region. AD BDEVs had significantly altered glycerophospholipid and sphingolipid levels, specifically increased plasmalogen glycerophosphoethanolamine and decreased polyunsaturated fatty acyl containing lipids, and altered amide‐linked acyl chain content in sphingomyelin and ceramide lipids relative to CTL. The most prominent alteration was a two‐fold decrease in lipid species containing anti‐inflammatory/pro‐resolving docosahexaenoic acid. The in‐depth lipidome analysis provided in this study highlights the advantage of EVs over more complex tissues for improved detection of dysregulated lipids that may serve as potential biomarkers in the periphery.

References 91

1. 1.

   Anand, S., Barnes, J. M., Young, S. A., Garcia, D. M., Tolley, H. D., Kauwe, J. S. K., & Graves, S. W. (2017 ). Discovery and confirmation of diagnostic serum lipid biomarkers for Alzheimer’s disease using direct infusion mass spectrometry. Journal of Alzheimer's Disease, 59, 277–290.

   Not in our library10.3233/jad-170035

2. 2.

   Bandaru, V. V., Troncoso, J., Wheeler, D., Pletnikova, O., Wang, J., Conant, K., & Haughey, N. J. (2009 ). ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiology of Aging, 30, 591–599.

   Not in our library10.1016/j.neurobiolaging.2007.07.024

3. 3.

   Barupal, D. K., Baillie, R., Fan, S., Saykin, A. J., Meikle, P. J., Arnold, M., Nho, K., Fiehn, O., Kaddurah‐DAOUK, R., & Alzheimer Disease Metabolomics, C. (2019 ). Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology. Alzheimers & Dementia, 11, 619–627.

   Not in our library10.1016/j.dadm.2019.07.002

4. 4.

   Bazinet, R. P., & Laye, S. (2014 ). Polyunsaturated fatty acids and their metabolites in brain function and disease. Nature Reviews Neuroscience, 15, 771–785.

   Not in our library10.1038/nrn3820

5. 5.

   Bennett, S. A., Valenzuela, N., Xu, H., Franko, B., Fai, S., & Figeys, D. (2013 ). Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease. Front Physiol, 4.

   Not in our library10.3389/fphys.2013.00168

6. 6.

   Brouwers, J. F., Aalberts, M., Jansen, J. W., Van Niel, G., Wauben, M. H., Stout, T. A., Helms, J. B., & Stoorvogel, W. (2013 ). Distinct lipid compositions of two types of human prostasomes. Proteomics, 13, 1660–1666.

   Not in our library10.1002/pmic.201200348

7. 7.

   Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., Wenk, M. R., SHUI, G., & Di PAOLO, G. (2012 ). Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. Journal of Biological Chemistry, 287, 2678–2688.

   Not in our library10.1074/jbc.m111.274142

8. 8.

   Chen, S., Datta‐Chaudhuri, A., Deme, P., Dickens, A., Dastgheyb, R., Bhargava, P., Bi, H., & Haughey, N. J. (2019 ). Lipidomic characterization of extracellular vesicles in human serum. Journal of Circulating Biomarkers, 8, 1849454419879848.

   Not in our library10.1177/1849454419879848

9. 9.

   Cheng, L., Vella, L. J., Barnham, K. J., Mclean, C., Masters, C. L., & Hill, A. F. (2020 ). Small RNA fingerprinting of Alzheimer's disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles. Journal of Extracellular Vesicles, 9, 1766822.

   Not in our library10.1080/20013078.2020.1766822

10. 10.

    Cutler, R. G., Kelly, J., Storie, K., Pedersen, W. A., Tammara, A., Hatanpaa, K., Troncoso, J. C., & Mattson, M. P. (2004 ). Involvement of oxidative stress‐induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proceedings of the National Academy of Sciences, 101, 2070–2075.

    Not in our library10.1073/pnas.0305799101

11. 11.

    Deleo, A. M., & Ikezu, T. (2018 ). Extracellular vesicle biology in Alzheimer's disease and related tauopathy. Journal of Neuroimmune Pharmacology, 13, 292–308.

    Not in our library10.1007/s11481-017-9768-z

12. 12.

    Dorninger, F., Forss‐Petter, S., & Berger, J. (2017 ). From peroxisomal disorders to common neurodegenerative diseases ‐ the role of ether phospholipids in the nervous system. Febs Letters, 591, 2761–2788.

    Not in our library10.1002/1873-3468.12788

13. 13.
    Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA · 2015

    No notice
14. 14.

    Fahy, E., Subramaniam, S., Brown, H. A., Glass, C. K., Merrill, A. H., Murphy, R. C., Raetz, C. R. H., Russell, D. W., Seyama, Y., Shaw, W., Shimizu, T., Spener, F., Van Meer, G., Vannieuwenhze, M. S., White, S. H., Witztum, J. L., & Dennis, E. A. (2005 ). A comprehensive classification system for lipids. Journal of Lipid Research, 46, 839–862.

    Not in our library10.1194/jlr.e400004-jlr200

15. 15.

    Fiala, M., Halder, R. C., Sagong, B., Ross, O., Sayre, J., Porter, V., & Bredesen, D. E. (2015 ). Omega‐3 supplementation increases amyloid‐beta phagocytosis and resolvin D1 in patients with minor cognitive impairment. Faseb Journal, 29, 2681–2689.

    Not in our library10.1096/fj.14-264218

16. 16.
    Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer’s disease · 2015

    Not checked
17. 17.

    Ginsberg, L., Rafique, S., Xuereb, J. H., Rapoport, S. I., & Gershfeld, N. L. (1995 ). Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Research, 698, 223–226.

    Not in our library10.1016/0006-8993(95)00931-f

18. 18.

    Glaser, P. E., & Gross, R. W. (1994 ). Plasmenylethanolamine facilitates rapid membrane fusion: A stopped‐flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane. Biochemistry, 33, 5805–5812.

    Not in our library10.1021/bi00185a019

19. 19.

    Gonzalez‐Dominguez, R., Garcia‐Barrera, T., & Gomez‐Ariza, J. L. (2014 ). Using direct infusion mass spectrometry for serum metabolomics in Alzheimer's disease. Analytical and Bioanalytical Chemistry, 406, 7137–7148.

    Not in our library10.1007/s00216-014-8102-3

20. 20.
    Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia · 2007

    Not checked
21. 21.

    Grimm, M. O., Kuchenbecker, J., Rothhaar, T. L., Grosgen, S., Hundsdorfer, B., Burg, V. K., Friess, P., Muller, U., Grimm, H. S., Riemenschneider, M., & Hartmann, T. (2011 ). Plasmalogen synthesis is regulated via alkyl‐dihydroxyacetonephosphate‐synthase by amyloid precursor protein processing and is affected in Alzheimer's disease. Journal of Neurochemistry, 116, 916–925.

    Not in our library10.1111/j.1471-4159.2010.07070.x

22. 22.

    Han, X., Fagan, A. M., Cheng, H., Morris, J. C., Xiong, C., & Holtzman, D. M. (2003 ). Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Annals of Neurology, 54, 115–119.

    Not in our library10.1002/ana.10618

23. 23.

    Han, X., Holtzman, D. M., & Mckeel, D. M. (2001 ). Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. Journal of Neurochemistry, 77, 1168–1180.

    Not in our library10.1046/j.1471-4159.2001.00332.x

24. 24.

    Han, X., Holtzman, D. M., Mckeel, D. M., Kelley, J., & Morris, J. C. (2002 ). Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: Potential role in disease pathogenesis. Journal of Neurochemistry, 82, 809–818.

    Not in our library10.1046/j.1471-4159.2002.00997.x

25. 25.
    Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics · 2011

    No notice
26. 26.

    Haraszti, R. A., Didiot, M. C., Sapp, E., Leszyk, J., Shaffer, S. A., Rockwell, H. E., Gao, F., Narain, N. R., Difiglia, M., Kiebish, M. A., Aronin, N., & Khvorova, A. (2016 ). High‐resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. Journal of Extracellular Vesicles, 5, 32570.

    Not in our library10.3402/jev.v5.32570

27. 27.

    Haughey, N. J., Bandaru, V. V. R., Bae, M., & Mattson, M. P. (2010 ). Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochimica et Biophysica Acta (BBA) ‐ Molecular and Cell Biology of Lipids, 1801, 878–886.

    Not in our library10.1016/j.bbalip.2010.05.003

28. 28.

    He, X., Huang, Y., Li, B., Gong, C.‐X., & Schuchman, E. H. (2010 ). Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiology of Aging, 31, 398–408.

    Not in our library10.1016/j.neurobiolaging.2008.05.010

29. 29.
    Current knowledge on exosome biogenesis and release · 2017

    No notice
30. 30.

    Hossain, M. S., Ifuku, M., Take, S., Kawamura, J., Miake, K., & Katafuchi, T. (2013 ). Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling. Plos One, 8, e83508.

    Not in our library10.1371/journal.pone.0083508

31. 31.

    Igarashi, M., Ma, K., Gao, F., Kim, H. W., Rapoport, S. I., & Rao, J. S. (2011 ). Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. Journal of Alzheimers Disease, 24, 507–517.

    Not in our library10.3233/jad-2011-101608

32. 32.

    Johnstone, R. M. A., Adam M., Hammond, J. R., Orr, L., & Turbide, C. (1987 ). Vesicle formation during reticulocyte maturation. The Journal of Biological Chemistry, 262, 9412–9420.

    Not in our library

33. 33.

    Kanninen, K. M., Bister, N., Koistinaho, J., & Malm, T. (2016 ). Exosomes as new diagnostic tools in CNS diseases. Biochimica et Biophysica Acta (BBA) ‐ Molecular Basis of Disease, 1862, 403–410.

    Not in our library10.1016/j.bbadis.2015.09.020

34. 34.

    Kastelowitz, N., & Yin, H. (2014 ). Exosomes and microvesicles: Identification and targeting by particle size and lipid chemical probes. Chembiochem, 15, 923–928.

    Not in our library10.1002/cbic.201400043

35. 35.

    Koal, T., Klavins, K., Seppi, D., Kemmler, G., & Humpel, C. (2015 ). Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid‐beta42, tau, and phospho‐tau‐181 levels. Journal of Alzheimers Disease, 44, 1193–1201.

    Not in our library10.3233/jad-142319

36. 36.
    Phospholipids and Alzheimer’s Disease: Alterations, Mechanisms and Potential Biomarkers · 2013

    No notice
37. 37.

    Kosicek, M., Zetterberg, H., Andreasen, N., Peter‐Katalinic, J., & Hecimovic, S. (2012 ). Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease. Neuroscience Letters, 516, 302–305.

    Not in our library10.1016/j.neulet.2012.04.019

38. 38.

    Laulagnier, K., Motta, C., Hamdi, S., Roy, S., Fauvelle, F., Pageaux, J., Kobayashi, T., Salles, J., Perret, B., Bonnerot, C., & Record, M. (2004 ). Mast cell‐ and dendritic cell‐derived exosomes display a specific lipid composition and an unusual membrane organization. The Biochemical Journal, 380, 161–171.

    Not in our library10.1042/bj20031594

39. 39.
    Role of exosomal proteins in cancer diagnosis · 2017

    No notice
40. 40.

    Llorente, A., Skotland, T., Sylvänne, T., Kauhanen, D., Róg, T., Orłowski, A., Vattulainen, I., Ekroos, K., & Sandvig, K. (2013 ). Molecular lipidomics of exosomes released by PC‐3 prostate cancer cells. Biochimica et Biophysica Acta (BBA) ‐ Molecular and Cell Biology of Lipids, 1831, 1302–1309.

    Not in our library10.1016/j.bbalip.2013.04.011

Cited by papers we hold 2

• Cell–cell communication: new insights and clinical implications · 2024
  No notice
• The lipid composition of extracellular vesicles: applications in diagnostics and therapeutic delivery · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.